biosimilars

Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Fierce Pharma
AbbVie
Boehringer Ingelheim
Humira
biosimilars
Flag link:
Pharma CEOs present united front - except on biosimilars
Pharma CEOs present united front - except on biosimilars
BioCentury
Senate
drug pricing
pharma executives
biosimilars
Flag link:
Canada Steers Away From Using Suffixes in Biologics' Names
Canada Steers Away From Using Suffixes in Biologics' Names
RAPS.org
Canada
United States
biologics
biosimilars
suffixes
Flag link:
Drugmakers Debate Whether Parts of FDA’s Biosimilar Guidance are Unconstitutional
Drugmakers Debate Whether Parts of FDA’s Biosimilar Guidance are Unconstitutional
RAPS.org
FDA
biosimilars
BLA
NDA
Flag link:
Rubio report outlines Chinese threat to U.S. biotech industry
Rubio report outlines Chinese threat to U.S. biotech industry
BioCentury
China
biotech
biosimilars
Marco Rubio
Flag link:
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
Fierce Pharma
Boehringer Ingelheim
AbbVie
biosimilars
Humira
patents
Flag link:
A War on High Drug Prices Could Boost Biosimilars
A War on High Drug Prices Could Boost Biosimilars
Motley Fool
drug pricing
biosimilars
Flag link:
Shakeup at the Top of FDA’s Biosimilars Division
Shakeup at the Top of FDA’s Biosimilars Division
RAPS.org
FDA
biosimilars
Flag link:
AbbVie loses $8B in market cap on steeper Humira erosion
AbbVie loses $8B in market cap on steeper Humira erosion
BioCentury
AbbVie
Humira
biosimilars
Flag link:
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
CP Wire
Coherus Biosciences
AbbVie
Humira
CHS-1420
biosimilars
Flag link:
Samsung Bioepis' First Cancer Biosimilar Approved by the FDA
Samsung Bioepis' First Cancer Biosimilar Approved by the FDA
BioSpace
FDA
Samsung Bioepis
Ontruzant
biosimilars
Genentech
Herceptin
Flag link:
FDA Approves 17th Biosimilar, Third for Herceptin
FDA Approves 17th Biosimilar, Third for Herceptin
RAPS.org
FDA
Merck
Samsung Bioepis
Ontruzant
biosimilars
Roche
Herceptin
Flag link:
Pfizer once again takes out the budget ax and lops off 150 R&D staffers and 5 preclinical biosimilar drugs
Pfizer once again takes out the budget ax and lops off 150 R&D staffers and 5 preclinical biosimilar drugs
Endpoints
Pfizer
R&D
biosimilars
layoffs
Flag link:
Are Scare Tactics Being Used to Avoid Biosimilar Competition?
Are Scare Tactics Being Used to Avoid Biosimilar Competition?
BioSpace
biosimilars
competition
drug marketing
Flag link:
FDA approves Celltrion's Herceptin biosimilar
FDA approves Celltrion's Herceptin biosimilar
BioCentury
FDA
Herceptin
biosimilars
Celltrion
HER2-positive metastatic breast cancer
Flag link:
FDA Rolls Out Expectations for Biosimilars, Soon-to-Be Biologics
FDA Rolls Out Expectations for Biosimilars, Soon-to-Be Biologics
RAPS.org
FDA
biosimilars
biologics
BPCIA
Flag link:
Biosimilar makers back Pfizer in call to end misleading brand marketing
Biosimilar makers back Pfizer in call to end misleading brand marketing
BioCentury
FDA
Pfizer
biosimilars
Flag link:
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
Fierce Pharma
AbbVie
biosimilars
Pfizer
Humira
patents
Flag link:
Spotlight on drug pricing could be catalyst for change in US biosimilar landscape
Spotlight on drug pricing could be catalyst for change in US biosimilar landscape
Endpoints
drug pricing
biosimilars
Flag link:
FDA approves first biosimilar for NHL
FDA approves first biosimilar for NHL
BioCentury
Celltrion
Teva Pharmaceutical
non-Hodgkin's lymphoma
Truxima
biosimilars
rituximab
Flag link:

Pages